Sun, Fumou
Cheng, Yan http://orcid.org/0000-0001-7877-9622
Wanchai, Visanu http://orcid.org/0000-0003-2243-3838
Guo, Wancheng
Mery, David
Xu, Hongwei
Gai, Dongzheng
Siegel, Eric http://orcid.org/0000-0001-9824-6612
Bailey, Clyde
Ashby, Cody http://orcid.org/0000-0002-9361-0283
Al Hadidi, Samer http://orcid.org/0000-0003-4297-8042
Schinke, Carolina http://orcid.org/0000-0002-2699-1741
Thanendrarajan, Sharmilan
Ma, Yupo
Yi, Qing http://orcid.org/0000-0003-1529-3398
Orlowski, Robert Z.
Zangari, Maurizio
van Rhee, Frits http://orcid.org/0000-0001-9959-1282
Janz, Siegfried http://orcid.org/0000-0002-2229-5511
Bishop, Gail http://orcid.org/0000-0002-1291-5078
Tricot, Guido
Shaughnessy, John D. Jr
Zhan, Fenghuang http://orcid.org/0000-0001-5417-2973
Funding for this research was provided by:
Foundation for the National Institutes of Health (1R01CA236814-01A1, 3R01-CA236814-03S1, U54CA272691-01, U54CA272691-01)
U.S. Department of Defense (CA180190, CA180190)
Myeloma Crowd Research Initiative Award, Paula and Rodger Riney Foundation, Myeloma Solution Fund, UAMS Winthrop P. Rockefeller Cancer Institute (WRCRI) Fund
Arkansas Breast Cancer Research Program
Article History
Received: 11 July 2023
Accepted: 9 January 2024
First Online: 19 January 2024
Competing interests
: F.S. and F.Z. are inventors on the patent application “Bispecific BCMA-CD24-CAR-T design”, describing the therapeutic use of BCMA-CD24-CAR-T cells for the treatment of multiple myeloma. The patent number is pending. The other authors declare no competing interests.